权威例句
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial *KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumoursPazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trialDebiec-Rychter, M. et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours...Debiec-Rychter M, Sciot R, Le Cesne A, Schlemmer M, Hohenberger P, van Oosterom AT et al.KIT mutations and dose selection for imatin...Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage c...Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an ...NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)–update of the NCCN clinical practice guid...Imatinib mesylate (STI-571 Glivec®, Gleevec™) is an active agent for gastrointestinal stromal tumours, but does not yield response...Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing ...
